Last reviewed · How we verify
Para-aminohippurate
Para-aminohippurate, marketed by Vanderbilt University Medical Center, is a drug with a well-established presence in its therapeutic area. A key strength is the protection afforded by its composition patent, which does not expire until 2028. The primary risk is the lack of clear revenue data, which may impact investment and market valuation.
At a glance
| Generic name | Para-aminohippurate |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes (PHASE1, PHASE2)
- Caveolin-1 and Vascular Dysfunction (PHASE1)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 (PHASE4)
- Renal Mechanism of SGLT2 Inhibition (PHASE2)
- MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (PHASE1)
- Effect of Acute Hypoxia on Renal Hemodynamic in Healthy Volunteers, Patients With Diabetes and Patients With Diabetes and Kidney Disease (NA)
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |